MELANOMA RECURRENT
Clinical trials for MELANOMA RECURRENT explained in plain language.
Never miss a new study
Get alerted when new MELANOMA RECURRENT trials appear
Sign up with your email to follow new studies for MELANOMA RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost immune attack on tough melanoma
Disease control OngoingThis study tests a new drug, BI-1607, added to two existing immunotherapy drugs (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or can't be removed. The goal is to see if the combination is safe and helps the immune system fight cancer better. Abo…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated May 17, 2026 04:25 UTC
-
Could one year of treatment be enough for advanced melanoma?
Disease control OngoingThis study tests whether giving the immunotherapy drug pembrolizumab for one year instead of the usual two years is just as effective for people with advanced melanoma that has spread. The trial involves 29 participants in Brazil's public health system. Researchers will track how…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug ST101 tested in patients with advanced cancers
Disease control OngoingThis study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…
Matched conditions: MELANOMA RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:58 UTC